La Jolla Pharmaceuticals
Abbott terminates development agreement with firm for lupus drug LJP 394 following assessment of a Phase II/III trial, which showed that the primary endpoint, time to renal flare, did not achieve statistical significance. La Jolla Pharmaceuticals is reducing its staff from 95 to 54, and will focus on pre-clinical development of a drug candidate for antibody-mediated thrombosis
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth